Literature DB >> 16249464

Autologous T-lymphocytes stimulate proliferation of orbital fibroblasts derived from patients with Graves' ophthalmopathy.

Stephen E Feldon1, D J John Park, Charles W O'Loughlin, Vu T Nguyen, Shira Landskroner-Eiger, Donald Chang, Thomas H Thatcher, Richard P Phipps.   

Abstract

PURPOSE: Graves' ophthalmopathy (GO) affects 50% to 60% of patients with Graves' hyperthyroidism, resulting in exophthalmos, periorbital edema, pain, double vision, optic neuropathy, and loss of vision. Fibroblasts are a key autoimmune target in GO and have effector functions that contribute to GO-associated pathologic conditions, including proliferation, production of excess glycosaminoglycans, and fat deposition. GO is also characterized by autoimmune inflammation of orbital connective tissue with mononuclear cell infiltration, including T cells.
METHODS: To determine whether autologous T cells can drive proliferation of orbital fibroblasts and thus contribute to GO, a novel reverse autologous mixed-cell reaction (rAMCR) was performed. Fibroblasts cultured from orbital tissue of patients with GO that was removed during orbital decompression surgery were mixed with autologous T cells, and fibroblast proliferation was determined.
RESULTS: Autologous T cells stimulated proliferation of orbital fibroblasts. Fibroblasts derived from blepharoplasty fat of two different patients did not proliferate, demonstrating that the effect is specific to cells derived from deep orbital fat. Proliferation was dependent on cell contact and on major histocompatibility complex (MHC) class II and CD40-CD154 (CD40 ligand) signaling.
CONCLUSIONS: The results suggest that T cells and orbital fibroblasts participate in an antigen-dependent positive feedback loop in which presentation of autoantigens by fibroblasts via MHC class II and CD40-CD40L signaling results in T-cell activation. These activated T cells stimulate fibroblast proliferation, leading to fibroblast-associated diseases in GO. Thus, therapies that interfere with CD40-CD40L signaling, antigen expression by fibroblasts, or T-cell function may be effective in preventing progression of GO symptoms.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16249464     DOI: 10.1167/iovs.05-0605

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  41 in total

1.  Immunotherapy for Graves' orbitopathy: easy enthusiasm, but let's keep trying.

Authors:  L Bartalena; M L Tanda
Journal:  J Endocrinol Invest       Date:  2006-12       Impact factor: 4.256

Review 2.  Cytokines, Graves' disease, and thyroid-associated ophthalmopathy.

Authors:  Andrew G Gianoukakis; Nicole Khadavi; Terry J Smith
Journal:  Thyroid       Date:  2008-09       Impact factor: 6.568

Review 3.  Graves' ophthalmopathy.

Authors:  Rebecca S Bahn
Journal:  N Engl J Med       Date:  2010-02-25       Impact factor: 91.245

Review 4.  The thyroid, the eyes and the gut: a possible connection.

Authors:  D Covelli; M Ludgate
Journal:  J Endocrinol Invest       Date:  2017-01-07       Impact factor: 4.256

Review 5.  Radiotherapy for Graves' disease. The possible role of low-dose radiotherapy.

Authors:  Meritxell Arenas; Sebastià Sabater; Pedro Lara Jiménez; Àngels Rovirosa; Albert Biete; Victoria Linares; Montse Belles; Julià Panés
Journal:  Rep Pract Oncol Radiother       Date:  2016-03-04

Review 6.  The eye and thyroid disease.

Authors:  Ajay E Kuriyan; Richard P Phipps; Steven E Feldon
Journal:  Curr Opin Ophthalmol       Date:  2008-11       Impact factor: 3.761

Review 7.  Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy.

Authors:  Terry J Smith; Chieh Chih Tsai; Mei-Ju Shih; Shanli Tsui; Beiling Chen; Rui Han; Vibha Naik; Chris S King; Chris Press; Shweta Kamat; Robert A Goldberg; Richard P Phipps; Raymond S Douglas; Andrew G Gianoukakis
Journal:  Thyroid       Date:  2008-09       Impact factor: 6.568

Review 8.  Recent insights into the pathogenesis and management of thyroid-associated ophthalmopathy.

Authors:  Andrew G Gianoukakis; Terry J Smith
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2008-10       Impact factor: 3.243

Review 9.  Platelet-derived growth factor: a key factor in the pathogenesis of graves' ophthalmopathy and potential target for treatment.

Authors:  Sita Virakul; Leendert van Steensel; Virgil A S H Dalm; Dion Paridaens; P Martin van Hagen; Willem A Dik
Journal:  Eur Thyroid J       Date:  2014-12-06

10.  Medical management of thyroid eye disease.

Authors:  Dawn D Yang; Mithra O Gonzalez; Vikram D Durairaj
Journal:  Saudi J Ophthalmol       Date:  2010-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.